News Solomon quits as Akari CEO following credit card probe Biotech veteran quits after less than a year in charge
News Akari soars ahead of read-out for Soliris rival Investors are anticipating good news from a potential rival to Alexion’s rare disease blockbuster Soliris, with shares in the company behind it soaring.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
